Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study

Autores de IDIVAL

• 

  Fernando Rivera Herrero

  Autor

  fernando.rivera@scsalud.es

Autores ajenos al IDIVAL

• Rha, SY
• Wyrwicz, LS
• Weber, PEY
• Bai, Y
• Ryu, MH
• Lee, J
• Alves, GV
• Garrido, M
• Shiu, KK
• Fernandez, MG
• Li, J
• Lowery, M
• Cil, T
• Cruz, FJSM
• Qin, S
• Yin, L
• Bordia, S
• Bhagia, P
• Oh, DY

Abstract

Abstract no disponible